Colchicine Duration for Acute Gout Flare
Colchicine should be continued daily until the gout flare completely resolves, not for a predetermined number of days. 1
Dosing Regimen
The treatment approach consists of two phases:
Initial Loading Dose
- 1.2 mg immediately, followed by 0.6 mg one hour later (total 1.8 mg over 1 hour) 1, 2
- This loading dose should be taken at the first sign of a flare
- Maximum dose for acute treatment: 1.8 mg over one hour 2
Maintenance Phase
Continue 0.6 mg once or twice daily until the flare resolves 1, 3
- The 2020 ACR guideline explicitly states: "ongoing anti-inflammatory therapy until the flare resolves" 1
- French Society of Rheumatology recommends: 0.5 mg, 2-3 times daily "over the next days" 3
- Duration is symptom-driven, not time-limited
Critical Dosing Adjustments
Renal Impairment
- Mild-moderate (CrCl 30-80 mL/min): Standard dosing acceptable with close monitoring 2
- Severe (CrCl <30 mL/min): Treatment course should not be repeated more than once every 2 weeks 2
- Dialysis patients: Single 0.6 mg dose only; repeat no more than once every 2 weeks 2
Drug Interactions
Do NOT treat acute flares with colchicine if the patient is already on prophylactic colchicine AND taking strong CYP3A4/P-gp inhibitors (clarithromycin, ritonavir, ketoconazole, etc.) 2
Important Clinical Caveats
Watch for diarrhea as the first sign of colchicine toxicity 3
- If diarrhea develops, reduce the dose immediately
- This occurs before other serious toxicities manifest
The "pills in pocket" strategy is strongly endorsed 1, 3
- Patients should self-administer at the earliest sign of flare (ideally within 12 hours of onset)
- Early treatment is far more effective than delayed treatment
Evidence Quality
The most recent and authoritative guidance comes from the 2020 ACR guideline 1, which supersedes the 2017 ACP recommendations 4. The ACR explicitly recommends continuing therapy "until the flare resolves" rather than specifying a fixed duration. This is supported by FDA labeling 2 and international guidelines 3.
The landmark trial 5 established that low-dose colchicine (1.8 mg total) is as effective as high-dose regimens with significantly fewer adverse events (23% vs 77% diarrhea rate), but this study only assessed 24-hour outcomes and did not address optimal continuation duration.
Bottom line: There is no predetermined number of days—continue until clinical resolution of the flare, which typically takes several days to a week.